Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use

被引：14

作者：

Fasanella, A. ^{[1
]}

Tonello, F. ^{[2
]}

Garofolo, G. ^{[1
]}

Muraro, L. ^{[2
]}

Carattoli, A. ^{[3
]}

Adone, R. ^{[3
]}

Montecucco, C. ^{[2
]}

机构：

[1] Ctr Nazl Referenza Antrace, Ist Zooprofilatt Sperimentale Puglia & Basilicata, I-71100 Foggia, Italy

[2] CNR, Ist Neurosci, Dipartimento Sci Biomed Padova, I-35121 Padua, Italy

[3] Ist Super Sanita, I-00161 Rome, Italy

来源：

VACCINE | 2008年 / 26卷 / 45期

关键词：

Anthrax; Inactive mutant toxins; Recombinant protective antigen; Vaccine;

D O I：

10.1016/j.vaccine.2008.08.026

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this study, the efficacy of two experimental vaccines against Bacillus anthracis toxinaemia was evaluated in the rabbit model. A recombinant Protective Antigen (rPA) mutant and a trivalent vaccine (TV) composed by the rPA, a inactive mutant of Lethal Factor (mLF-Y728A; E735A) and a inactive mutant of Edema Factor (mEF-K346R), both emulsified with mineral oils, were evaluated for their immunogenicity and protective activity in New Zealand white rabbits. Rabbits vaccinated subcutaneously with rPA and TV rapidly produced high level of anti-PA, anti-LF and anti-EF antibodies, which were still present 6 months later. In the efficacy test, these vaccines protected 100% of rabbits challenged with B. anthracis virulent strain 0843 one week after the vaccination. Moreover, all animals vaccinated twice with rPA and TV, resisted B. anthracis infection 6 months later. Our data indicate that rPA and TV could be good vaccine candidates for inducing protection against B. anthracis infection in target animal host. They could successfully be used in an emergency with simultaneous long-acting antibiotics to halt incubating infections or during an anthrax epidemic. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：5684 / 5688

页数：5

共 28 条

[1] Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen [J].

Aloni-Grinstein, R ;

Gat, O ;

Altboum, Z ;

Velan, B ;

Cohen, S ;

Shafferman, A .

INFECTION AND IMMUNITY, 2005, 73 (07) :4043-4053

[2]

[Anonymous], 2004, MAN DIAGN TESTS VACC

[3]

Buonavoglia D, 1998, MICROBIOLOGICA, V21, P209

[4] Bacillus anthracis virulence in guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonality [J].

Coker, PR ;

Smith, KL ;

Fellows, PF ;

Rybachuck, G ;

Kousoulas, KG ;

Hugh-Jones, ME .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (03) :1212-1218

[5] Anthrax toxin [J].

Collier, RJ ;

Young, JAT .

ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2003, 19 :45-70

[6] Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens [J].

Duverger, A ;

Jackson, RJ ;

van Ginkel, FW ;

Fischer, R ;

Tafaro, A ;

Leppla, SH ;

Fujihashi, K ;

Kiyono, H ;

McGhee, JR ;

Boyaka, PN .

JOURNAL OF IMMUNOLOGY, 2006, 176 (03) :1776-1783

[7] Molecular diversity of Bacillus anthracis in Italy [J].

Fasanella, A ;

Van Ert, M ;

Altamura, SA ;

Garofolo, G ;

Buonavoglia, C ;

Leori, G ;

Huynh, L ;

Zanecki, S ;

Keim, P .

JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (07) :3398-3401

[8] Detection of anthrax vaccine virulence factors by polymerase chain reaction [J].

Fasanella, A ;

Losito, S ;

Trotta, T ;

Adone, R ;

Massa, S ;

Ciuchini, F ;

Chiocco, D .

VACCINE, 2001, 19 (30) :4214-4218

[9]

FASANELLA A, 2006, INT VET VACC DIAGN C, P69

[10] Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice [J].

Firoved, AM ;

Miller, GF ;

Moayeri, M ;

Kakkar, R ;

Shen, YQ ;

Wiggins, JF ;

McNally, EM ;

Tang, WJ ;

Leppla, SH .

AMERICAN JOURNAL OF PATHOLOGY, 2005, 167 (05) :1309-1320

← 1 2 3 →